{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:32Z","timestamp":1790546192332,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020050","name":"Japan Intractable Diseases Research Foundation","doi-asserted-by":"publisher","award":["23FC1048"],"award-info":[{"award-number":["23FC1048"]}],"id":[{"id":"10.13039\/100020050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Precise epidemiological statistics regarding IgA nephropathy (IgAN) are essential for healthcare resource allocation and optimal therapeutic management. However, a nationwide epidemiological study has not been conducted in Japan over the past twenty years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a mail-based survey targeting departments at hospitals to estimate the annual numbers of patients with IgAN in 2022. Departments were selected using stratified random sampling based on specialty and hospital size, and a total of 2148 departments (nephrology, pediatrics, and urology) were included in the analysis. The overall and sex-specific annual numbers of patients with IgAN were estimated, along with the number of patients with high disease activity. The corresponding prevalence was calculated using these estimates, divided by the midyear population of Japan in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 702 departments responded to the survey representing an overall response rate of 32.7%. The estimated numbers of patients with IgAN were 103,800 (95% confidence interval [CI] 83,431\u00ad124,170), including 50,160 men (95% CI 40,034\u201360,287) and 53,640 women (95% CI 42,799\u00ad64,481). The annual prevalence of IgAN was 83.1 per 100,000 population (men: 82.6 women: 83.6), with a male-to-female ratio of 0.99. The estimated numbers of IgAN patients with high disease activity were 15,646 (95% CI 12,464\u00ad18,828).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This nationwide survey provides updated estimates of the prevalence of IgAN and the number of the IgAN patients with high disease activity in Japan. The prevalence of IgAN has risen substantially over the past twenty years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02948-0","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:57:14Z","timestamp":1790499434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The prevalence of IgA nephropathy in Japan: results from a nationwide survey"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-1574","authenticated-orcid":false,"given":"Keiichi","family":"Matsuzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryousuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Ohfuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakaba","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"2948_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/oxfordjournals.qjmed.a068143","volume":"64","author":"G D'Amico","year":"1987","unstructured":"D\u2019Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709\u201327.","journal-title":"Q J Med"},{"key":"2948_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, Rovin B. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107:640\u201351.","journal-title":"Kidney Int"},{"key":"2948_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859\u201370.","journal-title":"Lancet"},{"key":"2948_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402:2077\u201390.","journal-title":"Lancet"},{"key":"2948_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","volume":"394","author":"R Lafayette","year":"2026","unstructured":"Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, et al. A phase 3 trial of atacicept in patients with IgA nephropathy. N Engl J Med. 2026;394:647\u201357.","journal-title":"N Engl J Med"},{"key":"2948_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, et al. Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial. N Engl J Med. 2026;394:635\u201346.","journal-title":"N Engl J Med"},{"key":"2948_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38:435\u201342.","journal-title":"Semin Nephrol"},{"key":"2948_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s10157-021-02095-8","volume":"25","author":"H Suzuki","year":"2020","unstructured":"Suzuki H, Kikuchi M, Koike K, Komatsu H, Matsuzaki K, Takahashi K, et al. A digest from evidence-based clinical practice guideline for IgA nephropathy 2020. Clin Exp Nephrol. 2020;25:1269\u201376.","journal-title":"Clin Exp Nephrol"},{"key":"2948_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/qjmed\/hcm142","volume":"101","author":"O Moranne","year":"2008","unstructured":"Moranne O, Watier L, Rossert J, Stengel B, GN-Progress Study Group. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM. 2008;101:215\u201324.","journal-title":"QJM"},{"key":"2948_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ki.2013.329","volume":"85","author":"EP McQuarrie","year":"2014","unstructured":"McQuarrie EP, Mackinnon B, McNeice V, Fox JG, Geddes CC. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation. Kidney Int. 2014;85:198\u2013203.","journal-title":"Kidney Int"},{"key":"2948_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O'Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant. 2018;33:661\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000045404","volume":"82","author":"Research Group on Progressive Chronic Renal Disease","year":"1999","unstructured":"Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Nephron. 1999;82:205\u201313.","journal-title":"Nephron"},{"key":"2948_CR13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfn554","volume":"24","author":"FD Zhou","year":"2009","unstructured":"Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant. 2009;24:870\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.4103\/1319-2442.98195","volume":"23","author":"MA Habib","year":"2012","unstructured":"Habib MA, Badruddoza SM. Pattern of glomerular diseases among adults in Rajshahi, the northern region of Bangladesh. Saudi J Kidney Dis Transpl. 2012;23:876\u201380.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2948_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/0971-4065.85482","volume":"21","author":"U Das","year":"2011","unstructured":"Das U, Dakshinamurty KV, Prayaga A. Pattern of biopsy-proven renal disease in a single center of south India: 19 years experience. Indian J Nephrol. 2011;21:250\u20137.","journal-title":"Indian J Nephrol"},{"key":"2948_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152203","volume":"11","author":"IG Okpechi","year":"2016","unstructured":"Okpechi IG, Ameh OI, Bello AK, Ronco P, Swanepoel CR, Kengne AP. Epidemiology of histologically proven glomerulonephritis in Africa: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0152203.","journal-title":"PLoS ONE"},{"key":"2948_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/ki.2015.252","volume":"88","author":"R Magistroni","year":"2015","unstructured":"Magistroni R, D\u2019Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88:974\u201389.","journal-title":"Kidney Int"},{"key":"2948_CR18","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","volume":"38","author":"CJ Willey","year":"2023","unstructured":"Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38:2340\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR19","doi-asserted-by":"publisher","first-page":"sfaf068","DOI":"10.1093\/ckj\/sfaf068","volume":"18","author":"J Buisker","year":"2025","unstructured":"Buisker J, Behr S, Kubesch NJ, Turkson ME, Maes B, Kollins D, et al. The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency. Clin Kidney J. 2025;18:sfaf068.","journal-title":"Clin Kidney J"},{"key":"2948_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag021","author":"IK Ystr\u00f8m","year":"2026","unstructured":"Ystr\u00f8m IK, Jensen SK, Andersen IT, Ivarsen P, Christiansen CF. IgA nephropathy occurrence, treatment, and prognosis in the last two decades in Denmark. Nephrol Dial Transplant. 2026. https:\/\/doi.org\/10.1093\/ndt\/gfag021.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR21","first-page":"172","volume":"56","author":"JJ Sim","year":"2025","unstructured":"Sim JJ, Chen Q, Cannizzaro N, Bhandari SK, Fernandes AW, Chang J, et al. Incidence of adult primary immunoglobulin A nephropathy among a racially\/ethnically diverse population in the United States. Am J Nephrol. 2025;56:172\u20137.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2948_CR22","first-page":"442","volume":"50","author":"M Endo","year":"2008","unstructured":"Endo M. Epidemiology and prognosis of IgA nephropathy. Nihon Jinzo Gakkai Shi. 2008;50(4):442\u20137 (Japanese).","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"2948_CR23","unstructured":"Nakamura Y. The Study Group on Epidemiologic Research for Intractable Diseases. A manual of a nationwide epidemiological survey for estimating the number of patients and assessing clinicoepidemiological characteristics of patients with intractable diseases. 3rd ed. 2017. Available from: https:\/\/plaza.umin.ac.jp\/~nanbyouekigaku\/wp-content\/themes\/template\/assets\/pdf\/manual.pdf. Accessed 29 May 2026. (Japanese)"},{"key":"2948_CR24","unstructured":"Statistics Bureau of Japan. Current Population Estimates as of October 1, 2022. Available from: https:\/\/www.stat.go.jp\/english\/data\/jinsui\/2022np\/index.html. Accessed 29 May 2026."},{"key":"2948_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2188\/jea.10.29","volume":"10","author":"Y Nakamura","year":"2000","unstructured":"Nakamura Y, Matsumoto T, Tamakoshi A, Kawamura T, Seino Y, Kasuga M, et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol. 2000;10:29\u201333.","journal-title":"J Epidemiol"},{"key":"2948_CR26","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s11999-010-1292-x","volume":"468","author":"W Fukushima","year":"2010","unstructured":"Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 2010;468:2715\u201324.","journal-title":"Clin Orthop Relat Res"},{"key":"2948_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-018-2195-3","volume":"19","author":"H Mano","year":"2018","unstructured":"Mano H, Fujiwara S, Takamura K, Kitoh H, Takayama S, Ogata T, et al. Congenital limb deficiency in Japan: a cross-sectional nationwide survey on its epidemiology. BMC Musculoskelet Disord. 2018;19:262.","journal-title":"BMC Musculoskelet Disord"},{"key":"2948_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10157-019-01786-7","volume":"23","author":"A Fukui","year":"2018","unstructured":"Fukui A, Yokoo T, Nangaku M, Kashihara N. New measures against chronic kidney diseases in Japan since 2018. Clin Exp Nephrol. 2018;23:1263\u201371.","journal-title":"Clin Exp Nephrol"},{"key":"2948_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883\u20137.","journal-title":"Lancet"},{"key":"2948_CR30","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694\u2013701.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26\u201332.","journal-title":"Am J Kidney Dis"},{"key":"2948_CR32","doi-asserted-by":"publisher","first-page":"e194772","DOI":"10.1001\/jamanetworkopen.2019.4772","volume":"2","author":"K Hirano","year":"2019","unstructured":"Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open. 2019;2:e194772.","journal-title":"JAMA Netw Open"},{"key":"2948_CR33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"BH Rovin","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group, Rovin BH, Barratt J, Cook HT, Noronha IL, Reich HN, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108:S1\u201371.","journal-title":"Kidney Int"},{"key":"2948_CR34","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s40620-023-01687-9","volume":"36","author":"K Goto","year":"2007","unstructured":"Goto K, Imaizumi T, Hamada R, Ishikura K, Kosugi T, Narita I, et al. Renal pathology in adult and paediatric population of Japan: review of the Japan renal biopsy registry database from 2007 to 2017. J Nephrol. 2007;36:2257\u201367.","journal-title":"J Nephrol"},{"key":"2948_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000354646","volume":"38","author":"ZY Duan","year":"2013","unstructured":"Duan ZY, Cai GY, Chen YZ, Liang S, Liu SW, Wu J, et al. Aging promotes progression of IgA nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2013;38:241\u201352.","journal-title":"Am J Nephrol"},{"key":"2948_CR36","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMra020109","volume":"347","author":"JV Donadio","year":"2002","unstructured":"Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738\u201348.","journal-title":"N Engl J Med"},{"key":"2948_CR37","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ndt\/gfg207","volume":"18","author":"CC Geddes","year":"2003","unstructured":"Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AG, Ibels LS, et al. A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003;18:1541\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2948_CR38","first-page":"474","volume":"71","author":"ME Diebel","year":"2011","unstructured":"Diebel ME, Diebel LN, Liberati DM. Gender dimorphism in the gut: mucosal protection by estrogen stimulation of IgA transcytosis. J Trauma. 2011;71:474\u20139.","journal-title":"J Trauma"},{"key":"2948_CR39","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.34067\/KID.0002972021","volume":"2","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Monteiro RC, Coppo R, Suzuki H. The phenotypic difference of IgA nephropathy and its race\/gender-dependent molecular mechanisms. Kidney360. 2021;2:1339\u201348.","journal-title":"Kidney360"},{"key":"2948_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024317","volume":"8","author":"Y Okabayashi","year":"2018","unstructured":"Okabayashi Y, Tsuboi N, Amano H, Miyazaki Y, Kawamura T, Ogura M, et al. Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: a cross-sectional study. BMJ Open. 2018;8:e024317.","journal-title":"BMJ Open"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02948-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:01:58Z","timestamp":1790542918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":40,"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02948-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Keiichi Matsuzaki has received consulting fees from Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K, and Taisho Audit Inc.; honoraria for lectures from Kyowa Kirin Co., Ltd. and Novartis Pharma K.K; and research funding from the Sunstar Foundation. Yusuke Suzuki has received consulting fees from Otsuka Pharmaceutical (Visterra), Novartis, Chinook Therapeutics, Argenx, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine, and George Clinical, as well as honoraria from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, and Chinook Therapeutics.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed according to ethical guidelines for medical and health research involving human subjects provided by the Japanese Ministry of Health, Labour and Welfare, as well as the Declaration of Helsinki. The protocol of this investigation was approved by the Ethics Committee of Osaka Metropolitan University (No. 2024-088).","order":2,"name":"Ethics","label":"Research involving human participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An opt-out option was provided, as explained in information posted on the institutional website.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}